백신 보조제 시장(2025-2034년) : 기회, 성장 촉진요인, 산업 동향 분석, 예측

The Global Vaccine Adjuvants Market reached USD 1.3 billion in 2024 and is projected to expand at a CAGR of 6.5% from 2025 to 2034. Vaccine adjuvants are added to vaccines to amplify the immune system's response to the antigen. By enhancing immune responses, adjuvants increase the effectiveness of vaccines, ensuring stronger and longer-lasting protection. They also allow for the use of smaller amounts of the antigen, making vaccines more cost-effective while improving their overall efficiency.

The market is categorized by product types, which include saponin-based adjuvants, adjuvant emulsions, pathogen components, particulate adjuvants, and others. Among these, particulate adjuvants led the market in 2024, accounting for 35.4% of revenue. The rising prevalence of infectious diseases globally has intensified the demand for vaccines with higher efficacy. Particulate adjuvants are crucial in improving immune responses, making them a key element in vaccine development. Their effectiveness in boosting immune activity is vital for tackling widespread health concerns, underlining their growing importance in vaccine formulations.

Another significant market segmentation is based on the route of administration, including intramuscular, subcutaneous, oral, and other methods. The intramuscular route dominated the market in 2024, holding a 59.3% share, and is expected to continue its upward trajectory, reaching USD 1.4 billion by 2034. Vaccines administered intramuscularly with adjuvants have proven to trigger strong and long-lasting immune responses, which are particularly important for populations at higher risk of infectious diseases. The increased demand for effective vaccines, particularly following global health challenges, has further emphasized the importance of intramuscular adjuvant administration. This method enhances vaccine performance and plays a critical role in vaccination campaigns worldwide.

U.S. vaccine adjuvants market is anticipated to see substantial growth, reaching USD 927.5 million by 2034. Key U.S. government agencies invest in vaccine research, focusing on improving adjuvants to boost vaccine efficacy against a wide range of diseases. Moreover, collaborative efforts between pharmaceutical companies, academic institutions, and research organizations are driving innovation in the field, paving the way for new and improved adjuvant technologies that will play a pivotal role in enhancing future vaccine formulations.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing demand for effective and long-lasting immunity
    • 3.2.1.2 Growing prevalence of infectious diseases and pandemics
    • 3.2.1.3 Increased government and private funding for vaccine development
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs and lengthy development timelines
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Pipeline analysis
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Adjuvant emulsions
• 5.3 Pathogen components
• 5.4 Saponin-based adjuvants
• 5.5 Particulate adjuvants
• 5.6 Other product types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Intramuscular
• 6.3 Subcutaneous
• 6.4 Oral
• 6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Infectious diseases
• 7.3 Cancer
• 7.4 Other diseases

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Human vaccines
• 8.3 Veterinary vaccines

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Agenus
• 10.2 Allergy Therapeutics
• 10.3 Aurorium
• 10.4 Brenntag Biosector
• 10.5 Croda International
• 10.6 CSL Limited
• 10.7 Dynavax Technologies Corporation
• 10.8 EuBiologics
• 10.9 GSK plc
• 10.10 Merck KGaA
• 10.11 Novavax
• 10.12 OZ Biosciences
• 10.13 Riboxx GmbH
• 10.14 Seppic
• 10.15 SPI Pharma